Three years ago, TG Therapeutics had almost no revenue and a stock that traded mostly on hope. Today it has a drug generating nearly a billion dollars a year and a balance sheet that is, for the first time in the company’s history, genuinely comfortable. Those two facts create a tension worth examining: a price-to-earnings multiple sitting at a multi-decade low relative to its own history, even as the underlying business has materially improved. Whether that gap reflects disciplined risk-pricing or a lag in market recognition is the question the data can frame but not resolve.
That gap, between a business that has demonstrably arrived and a valuation that treats it like a question mark, is the story worth reading carefully.
The short version
The filed numbers show a company that went from near-zero revenue to nearly a billion dollars in annual sales in three years, with net margins expanding sharply and cash on hand exceeding half a billion dollars. The stock trades at a price-to-earnings multiple well below its own historical median, which our data puts at the 20th percentile of its decade range. The open question is whether the market is being disciplined about real risks, including heavy reinvestment spending and a pipeline that has not yet proven it can repeat BRIUMVI’s success, or whether it is simply slow to update on a transformation that the filings already confirm.
How a single approval changed everything
For most of its life, TG Therapeutics was a company spending money it did not earn, funding clinical trials with equity raises and hoping one of its programs would break through. The FDA approval of BRIUMVI on December 28, 2022, for relapsing forms of multiple sclerosis, changed the arithmetic entirely. The drug launched commercially in early 2023, and the revenue line went from negligible to hundreds of millions in a single fiscal year. That is not a rounding error. That is a company being born twice.
By fiscal year 2025, the 10-K filed in early 2026 showed total revenue of $616 million, nearly double the prior year, with U.S. BRIUMVI net product sales accounting for the vast majority of that figure. The net margin, which is what is left of each dollar of revenue after every cost including taxes, reached 72.6% for the full year. A drug company earning more than seventy cents of profit on every dollar of sales is not a struggling biotech. It is a mature pharmaceutical business wearing a biotech’s clothes.
The operating margin, a narrower measure that strips out financing items and taxes, widened meaningfully from 2024 to 2025. That direction matters as much as the level. A business where margins are expanding is one where each new dollar of revenue costs less to produce than the last.
Where the money is going now
The 10-Q for the quarter ended June 30, 2026 shows a company in a deliberate spending phase. R&D expense for the second quarter alone reached $95 million, more than half of it tied to manufacturing work on a subcutaneous version of BRIUMVI, a formulation patients could eventually self-inject at home rather than receiving an intravenous infusion at a clinic. That is a meaningful convenience upgrade, and the company is paying for it now in hopes of protecting and extending its market position later.
The spending did not produce a loss. Net income for Q2 2026 was thin but positive, and the cash position actually grew during the quarter to $612 million. Think of it this way: a household earning enough to cover its bills and still add a little to savings, while also renovating the kitchen for the next decade. The renovation costs are real, but the household is not in distress.
Management guided full-year 2026 operating expenses, excluding stock-based compensation, to a range of $350 million to $400 million, plus a substantial additional commitment for manufacturing. That is a significant outlay, and it is the reason the quarterly earnings-per-share figure came in below what analysts had expected, as Zacks reported following the August earnings release. The market noticed. The stock fell on the day. Whether that reaction reflects a genuine concern about profitability or an impatience with a company that is reinvesting aggressively into a growing franchise is the question the filings alone cannot answer.
The pipeline bet inside the valuation
In April 2026, TG Therapeutics completed enrollment for the Phase 3 trial of subcutaneous BRIUMVI, with topline data expected around year-end 2026 or early 2027. A positive result would support a filing for a new formulation that could meaningfully expand the drug’s addressable market. A negative result would not kill the franchise, since the intravenous version is already approved and selling, but it would remove a growth narrative the market has been pricing in.
Beyond the subcutaneous program, the company has initiated trials in myasthenia gravis and, in July 2026, began a Phase 2 study in treatment-resistant schizophrenia. The schizophrenia program is early and speculative. The myasthenia gravis program, following positive Phase 1 data in June 2026, is described on the Q2 2026 earnings call as potentially registration-directed, meaning a successful Phase 2 could lead directly to a regulatory filing. These are options on future revenue, not current revenue, and the market assigns them value based on probability and timing, both of which are genuinely uncertain.
The March 2026 credit facility with Blue Owl Capital, a large senior secured arrangement that delivered substantial net new capital without issuing new shares, tells you something about management’s intentions. They locked in long-term financing at a fixed rate rather than diluting shareholders, and they simultaneously expanded the share repurchase program to a meaningful size. A company that is buying back its own shares is allocating capital in a way that reduces the share count; management’s stated rationale, as disclosed in the March 2026 announcement, was capital efficiency. Whether that allocation proves well-timed depends on factors the filings do not resolve.
What the math says and what the mood is paying
“The math” is what the filed fundamentals justify on their own terms. “The mood” is what the market is currently willing to pay for those fundamentals. When the two diverge, that gap is usually where the interesting question lives.
Our data shows TGTX trading at a price-to-earnings multiple of 19 times, which sits at the 20th percentile of its own decade range. The decade median has been far higher, though that figure reflects years when the company had almost no earnings and the multiple was mathematically enormous. A more useful observation is the price-to-sales ratio, which sits below the company’s own decade median and carries a premium to the broader biotechnology and pharmaceuticals sector. Whether that premium is justified by the growth rate, which ran at roughly double the prior year in fiscal 2025, is the arithmetic question at the center of the valuation debate.
The central valuation question, how much of the operational improvement is already reflected in the current price, is not resolved by the filings alone. The company raised its full-year 2026 global revenue guidance to approximately $950 million, and CEO Mike Weiss, speaking on the Q2 2026 earnings call, described BRIUMVI as being “on a path toward a $1 billion annual run rate” by year-end. Multiple sell-side firms cover TGTX; their published estimates, which BullScope does not adopt or endorse, are publicly available through standard financial data services. A governance investigation announced in late September 2026 into potential self-dealing by officers and directors added what the dossier research describes as a “governance overhang,” a cloud of uncertainty that has nothing to do with the drug’s performance and everything to do with how much distraction it creates.
The data cannot tell us how the subcutaneous trial reads out, whether the governance investigation resolves cleanly, or whether BRIUMVI’s market share gains continue at the same pace. Those are the open questions. What the filings do confirm is that the underlying business, measured by revenue growth, margin expansion, and cash generation, has already cleared the bar that most biotech investors spend years waiting for. The mood and the math are not yet reading from the same page. That disagreement, and the open questions that explain it, is what the filed evidence can frame but not resolve.
Reading the numbers
- FY2025 revenue: $616 million (from the 10-K for fiscal year ended December 31, 2025). What it is: total sales for the year. What it means here: the company nearly doubled its revenue in a single year, driven almost entirely by one drug. Everyday terms: imagine a restaurant that served 500 tables last year and served 940 this year, with the same menu. That is the scale of the change.
- Net margin of 72.6% in FY2025. What it is: the share of each revenue dollar that becomes profit after all costs. What it means here: for every dollar BRIUMVI brought in, the company kept more than seventy cents. Everyday terms: a bakery that charges $10 for a loaf and keeps $7.26 after flour, labor, rent, and taxes is an unusually profitable bakery.
- Q2 2026 R&D spending: $95 million (from the 10-Q for quarter ended June 30, 2026). What it is: money spent on research and development in a single quarter. What it means here: the company is spending at a rate that exceeds its entire 2024 annual R&D budget in just three months, a sign of deliberate acceleration. Everyday terms: a household that spent $10,000 on home improvements all of last year is now spending that much every three months. The house is not falling apart; the owners are upgrading it.
- P/E of 19 times, at the 20th percentile of its own decade range (our data). What it is: the price-to-earnings multiple, meaning how many dollars the market pays for each dollar of annual profit. What it means here: relative to its own history, the stock is priced cheaply, even though the underlying business is performing better than it ever has. Everyday terms: a restaurant that was once valued at $2 million when it was losing money is now valued at $1 million when it is profitable. The price went down as the business got better. That is the tension.
- Cash position: $612 million as of June 30, 2026 (from the 10-Q for quarter ended June 30, 2026). What it is: money in the bank plus short-term investments. What it means here: the company holds roughly one full year of its own revenue in liquid assets, giving it room to fund trials and manufacturing without needing to raise new capital. Everyday terms: a family with a year’s salary sitting in savings has options that a family living paycheck to paycheck does not.
Sources
- TGTX 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- TGTX 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- TGTX Q2 2026 earnings call transcript (Motley Fool)
- TGTX Q2 2026 earnings coverage (Zacks)
- Blue Owl credit facility announcement, March 2026 (GlobeNewswire)
- Phase 3 subcutaneous enrollment completion, April 2026 (GlobeNewswire)
- BRIUMVI FDA approval, December 2022 (NeurologyLive)
- TGTX analyst coverage overview (MarketBeat)
- TGTX valuation commentary, September 2026 (DirectorsTalkInterviews, citing Simply Wall St.)
